Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimization of Individualized Therapy for CRCs With Secondary RESISTance Towards Anti-EGFR Targeted Therapy Using an Avatar Model (Colon-Resist-Net)

NCT03263663 is registered in ClinicalTrials.gov with PD Dr. med. Volker Heinemann as lead sponsor.

NCT NCT03263663
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03263663 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimization of Individualized Therapy for CRCs With Secondary RESISTance Towards Anti-EGFR Targeted Therapy Using an Avatar Model (Colon-Resist-Net)
Lead sponsor
PD Dr. med. Volker Heinemann
Phase
Observational
Overall status
Unknown status
Start date
January 1, 2017
Completion date
January 1, 2025
Enrollment
1,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colo-rectal cancer, ras wild-type, uicc ii + rf, uicc iii, uicc iv curative intent